Division of Thoracic Surgery, Swedish Cancer Institute and Medical Center, Seattle, WA, USA.
J Gastrointest Surg. 2013 Dec;17(12):2045-50. doi: 10.1007/s11605-013-2357-4. Epub 2013 Sep 25.
Self-expanding fully covered metal stents (CSs) are ideal for use in benign esophagogastric disease. We reviewed our experience with CS to evaluate outcomes, to determine a role for CS in a standard treatment for benign esophageal conditions, and to compare our results with recently published studies.
We performed a retrospective chart review from 2005 to 2012.
A total of 57 CSs were placed in 44 patients. Indications were stricture (11 patients), anastomotic leak (20), perforation (7), and tracheoesophageal fistulae (6). For GI tract disruptions, open repair or diversion was avoided in 31/33 patients (93.9 %) but required an associated drainage procedure in 22/33 (67 %) patients. Resolution does not depend on achieving radiological control with 6/26 (23 %) having evidence of a persistent leak. Benign strictures were dilated at a mean of 3.7 times prior to stenting. Adjunctive intra-mucosal steroid injections were used in 8/11 patients. Stents were removed at a mean of 33 days. At a mean of 283 days of follow-up, 6/11 (54.5 %) had symptom resolution. The most common complication was stent migration occurring in 17.5 % of patients overall.
Covered stents are an effective adjunct in the management of benign upper gastrointestinal tract fistulae, leaks, perforations and benign strictures.
自膨式全覆膜金属支架(CS)是治疗良性胃食管疾病的理想选择。我们回顾了 CS 的使用经验,以评估其疗效,确定 CS 在良性食管疾病标准治疗中的作用,并将我们的结果与最近发表的研究进行比较。
我们对 2005 年至 2012 年的病历进行了回顾性分析。
共对 44 例患者的 57 枚 CS 进行了治疗。适应证为狭窄(11 例)、吻合口漏(20 例)、穿孔(7 例)和气管食管瘘(6 例)。对于胃肠道破裂,33 例患者中的 31 例(93.9%)避免了开放修复或分流,但 22 例(67%)患者需要相关的引流术。6 例(23%)患者仍有持续漏的影像学证据,但并不依赖于获得影像学控制来判断是否治愈。良性狭窄在支架置入前平均扩张 3.7 次。11 例患者中有 8 例接受了黏膜内类固醇注射辅助治疗。支架平均取出时间为 33 天。平均随访 283 天后,11 例患者中有 6 例(54.5%)症状缓解。最常见的并发症是支架移位,总体发生率为 17.5%。
覆膜支架是治疗良性上消化道瘘、漏、穿孔和良性狭窄的有效辅助手段。